Strategies for optimizing immunosuppression in adolescent transplant recipients: A focus on liver transplantation

Pediatric Drugs

Volumn 5, Issue 3, 2003, Pages 177-183

  Kelly, Deirdre A ^a  

^a BIRMINGHAM CHILDREN S HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; CORTICOSTEROID; CYCLOSPORIN; CYCLOSPORIN A; DACLIZUMAB; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RAPAMYCIN; TACROLIMUS;

ADOLESCENCE; ANEMIA; ARTERY THROMBOSIS; BONE MARROW SUPPRESSION; CUSHINGOID SYNDROME; DIARRHEA; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; FERTILITY; GASTROINTESTINAL SYMPTOM; GINGIVA HYPERPLASIA; GRAFT REJECTION; GROUPS BY AGE; HIRSUTISM; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; LIVER TRANSPLANTATION; LYMPHOPROLIFERATIVE DISEASE; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; PATIENT COMPLIANCE; PREGNANCY; PRIORITY JOURNAL; RECIPIENT; REVIEW; SIDE EFFECT; TERATOGENICITY; THROMBOCYTOPENIA; TREATMENT PLANNING; WEIGHT GAIN; WOUND HEALING;

EID: 0037232369     PISSN: 11745878     EISSN: None     Source Type: Journal    
DOI: 10.2165/00128072-200305030-00004     Document Type: Review

References (53)

1. Viner R, Keane M. Youth matters: evidence based practice for the care of young people in hospital. London: NHS, 1999 (Caring for children in the health service series)
2. McKinney JP, Fitzgerald HE, Strommen EA. The adolescent and the young adult. Chicago (IL): Dorsey Press, 1997
3. Kelly DA. Current results and evolving indications for liver transplantation in children. J Pediatr Gastroenterol Nutr 1998; 27: 214-21
4. Goss JA, Shackleton CR, McDiarmid SV, et al. Long-term results of pediatric liver transplantation: an analysis of 569 transplants. Ann Surg 1998; 228 (3): 411-20
5. Molmenti E, Mazariegos G, Bueno T, et al. Noncompliance after paediatric liver transplantation. Trans Proc 1999; 31: 408
6. Watson AR. Non-compliance and transfer from paediatric to adult transplant unit. Pediatr Nephrol 2000; 14 (6): 469-72
7. Benfield MR, Stablein D, Tejani A. Trends in immunosuppressive therapy: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Pediatr Transplant 1999; 3 (1): 27-32
8. Niles DG, Rynearson RD, Baum M, et al. A study of craniofacial growth in infant heart transplant recipients receiving cyclosporine. J Heart Lung Transplant 2000; 19 (3): 231-9
9. Achilleos OA, Mirza DF, Talbot D, et al. Outcome of liver retransplantation in children. Liver Transplant Surg 1999; 5: 401-6
10. Sieders E, Peeters PM, Ten Vergert EM, et al. Retransplantation of the liver in children. Transplantation 2001; 71: 90-5
11. Male D, Roitt I, Bostoff J, editors. Immunology. 5th ed. St Louis (MO): Mosby Company, 1998
12. Arora N, Bunn S, McKiernan P, et al. Long term evaluation of renal function after paediatric liver transplantation [abstract]. Hepatology 2000; 32: 341A
13. Bartosh SM, Alonso EM, Whitington PF. Renal outcomes in pediatric liver transplantation. Clin Transplant 1997; 11 (5 Pt I): 354-60
14. Berg UB, Ericzon BG, Nemeth A. Renal function before, and long after liver transplantation in children. Transplantation 2001; 27: 561-2
15. Reyes J, Jain A, Mazariegos G, et al. Long-term results after conversion from cyclosporine to tacrolimus in pediatric liver transplantation for acute and chronic rejection. Transplantation 2000; 69: 2578-80
16. Cacciarelli TV, Reyes J, Jaffe R, et al. Primary tacrolimus (FK506) therapy and the long-term risk of post transplant lymphoproliferative disease in paediatric liver transplant recipients. Pediatr Transplant 2001; 5: 359-64
17. Haagsma EB, Hagens VE, Schaapveld M, et al. Increased cancer risk after liver transplantation: a population based study. J Hepatol 2001; 34: 84-91
18. Rodek B, Melter M, Hoyer PF, et al. Growth in long term survivors after orthotopic liver transplantation in childhood. Transplant Proc 1994; 26: 165-6
19. Andrews W, Sommerauer J, Roden J, et al. 10 years of pediatric liver transplantation. J Pediatr Surg 1996; 31: 619-24
20. Kelly DA. Post transplant growth failure in children. Liver Transplant Surg 1997; 3: 1-9
21. Evans H, McKiernan P, Beath S, et al. Histology of liver allografts following paediatric liver transplantation [abstract]. J Pediatr Gastroenterol Nutr 2001; 32: 383
22. Evans H, McKiernan P, Beath S, et al. Progressive liver pathology in long term survivors of paediatric liver transplantation [abstract]. Hepatology 2001; 34: 246A
23. Spada M, Corno V, Colledan M. Rejection and tacrolimus conversion therapy in paediatric liver transplantation. Transpl Int 2000; 13: S341-4
24. Furlan V, Debray D, Fourre C, et al. Conversion from cyclosporin A to tacrolimus in paediatric liver transplantation. Pediatr Transplant 2000; 4: 207-10
25. Kelly D, Jara P, Rodeck B, et al. Tacrolimus dual therapy versus cyclosporin microemulsion triple therapy in paediatric liver transplantation: results from a multicentre randomised trial [abstract]. Am J Transpl 2002; 3: 351
26. Jain A, Mazariegos G, Kashyap R, et al. Comparative long-term evaluation of tacrolimus and cyclosporin in paediatric liver transplantation. Transplantation 2000; 70: 617-25
27. Chardot C, Nicoluzzi JE, Janssen M, et al. Use of mycophenolate mofetil as rescue therapy after paediatric liver transplantation. Transplantation 2001; 71: 224-9
28. Renz JF, Lightdale J, Mudge C, et al. Mycophenolate mofetil, microemulsion cyclosporin, and prednislone as primary immunosuppression for pediatric liver transplant recipients. Liver Transpl Surg 1999; 5: 136-43
29. Evans HM, McKiernan PJ, Beath SV, et al. Mycophenolate mofetil in patients with renal dysfunction following paediatric liver transplantation [abstract]. J Pediatr Gastroenterol Nutr 2001; 32: 383
30. Aw MM, Samaroo B, Baker AJ, et al. Calcineurin inhibitor related nephrotoxicity reversibility in paediatric liver transplant recipients. Transplantation 2001; 72: 746-9
31. Sehgal SN. Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin Biochem 1998; 31: 335-40
32. Macdonald AS, for the Rapamune Global Study Group. A worldwide, phase III, randomised, controlled safety efficacy study of a sirolimus/cyclosporin regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation 2001; 71: 271-80
33. McAlister VC, Peltekian KM, Malatjalian DA, et al. Orthotopic liver transplantation using low-dose tacrolimus and sirolimus. Liver Transpl 2001; 7: 401-8
34. Pappas PA, Weppler D, Pinna AD, et al. Sirolimus in paediatric gastrointestinal transplantation: the use of sirolimus for paediatric transplant patients with tacrolimus-related cardiomyopathy. Pediatr Transpl 2000; 4: 45-9
35. Berard JL, Velez RL, Freeman RB, et al. A review of interleukin-2 receptor antagonists in solid organ transplantation. Pharmacotherapy 1999; 19: 1127-37
36. Ganschow R, Broering DC, Stuerenburg I, et al. First experience with basiliximab in paediatric liver graft recipients. Pediatr Transpl 2001; 5: 353-8
37. Riordan SM, Williams R. Tolerance after liver transplantation: does it exist and can immunosuppression be withdrawn. J Hepatol 1999; 31 (6): 1106-19
38. Ramos HC. Reyes J, Abu-Elmagd K, et al. Weaning of immunosuppression in long term liver transplant recipients. Transplantation 1995; 59: 212-7
39. Reyes J, Zeevi A, Tzakis A, et al. The frequent achievement of a drug-free state after orthotopic liver transplantation. Transplant Proc 1993; 25: 3315-9
40. Murphy MS, Harrison R, Davies P, et al. Risk factors for liver rejection: evidence to suggest enhanced allograft tolerance in infancy. Arch Dis Child 1996; 75: 502-6
41. Ganschow R, Broering DC, Nolkempter D, et al. Th2 cytokine profile in infants predisposes to improved graft acceptance after liver transplantation. Transplantation 2001; 72: 929-34
42. Takatsuki M, Uemoto S, Inomata Y, et al. Weaning of immunosuppression in living donor liver transplant recipients. Transplantation 2001; 72 (3): 449-54
43. Reding R, de Goyet Jde V, Delbeke I, et al. Pediatric liver transplantation with cadaveric or living related donors: comparative results in 90 elective recipients of primary grafts. J Pediatr 1999; 134 (3): 280-6
44. Katz SM, Ozaki CF, Monsour Jr HP. Pediatric living-related and cadaveric liver transplantation: a single center experience. Transplant Proc 1994; 26 (1): 145-6
45. Gupta P, Hart J, Cronin D, et al. Risk factors for chronic rejection after pediatric liver transplantation. Transplantation 2001; 72 (6): 1098-102
46. Codoner-Franch P, Bernard O, Alvarez F. Long-term follow up of growth and height after successful liver transplantation. J Pediatr 1994; 124: 368-73
47. Cundy TF, O'Grady JG, Williams R. Recovery of menstruation and pregnancy after liver transplantation. Gut 1990; 31: 337-8
48. Hou S. Pregnancy in chronic renal insufficiency and end stage renal disease. Am J Kidney Dis 1999; 33: 235-52
49. Fraser FC, Sajoo A. Teratogenic potential of corticosteroids in humans. Teratology 1995; 51: 45-6
50. Armenti VT, Mortiz MJ, Davison JM. Drug safety issues in pregnancy following transplantation and immunosuppression: effects and outcomes. Drug Saf 1998; 19: 219-32
51. Casele HL, Laifer SA. Pregnancy after liver transplantation. Semin Perinatol 1998; 22: 149-55
52. Kainz A, Harabacz I, Cowlrick IS, et al. Analysis of 100 pregnancy outcomes in women treated systemically with tacrolimus. Transpl Int 2000; 13 Suppl. 1: S299-300
53. Nyberg G, Haljamae U, Frisenette-Fich CM, et al. Breast feeding during treatment with cyclosporin. Transplantation 1998; 65: 253-5